COVID vaccine makers shift focus to producing booster shots

COVID vaccine makers shift focus to boosters COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months. Michael Erman,Manas Mishra Reuters

Executives at the biggest COVID vaccine makers including Pfizer Inc (PFE.N) and Moderna Inc (MRNA.O) said they believe most people who wanted to get vaccinated against COVID have already done so - more than 5 billion people worldwide.

In the coming year, most COVID vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said.

Pfizer, which makes its shot with Germany's BioNTech SE (22UAy.DE), and Moderna still see a major role for themselves in the vaccine market even as overall demand declines.

Upstart U.S. vaccine maker Novavax Inc (NVAX.O) and Germany's CureVac NV (5CV.DE), which is working with GlaxoSmithKline (GSK.L), are developing vaccines they hope to target at the booster market. 

The roles of AstraZeneca Plc (AZN.L) and Johnson & Johnson (JNJ.N), whose shots have been less popular or effective, are expected to decline in this market.

...